EMEA Will Evaluate All NSAIDs In Search Of Potential “Class Effect”
This article was originally published in The Tan Sheet
Executive Summary
The EU health authority will undertake its own review of all non-steroidal anti-inflammatory drugs in light of safety concerns surrounding COX-2 inhibitors
You may also be interested in...
EMEA Calls For NSAID Labeling Consistency, Notes “No New Safety Concerns”
Labeling regarding established NSAID safety concerns should be made consistent across European Union member states, the European Medicines Agency said Oct. 17
EMEA Calls For NSAID Labeling Consistency, Notes “No New Safety Concerns”
Labeling regarding established NSAID safety concerns should be made consistent across European Union member states, the European Medicines Agency said Oct. 17
EMEA Calls For NSAID Labeling Consistency, Notes “No New Safety Concerns”
Labeling regarding established NSAID safety concerns should be made consistent across European Union member states, the European Medicines Agency said Oct. 17